{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:35:02Z","timestamp":1766133302030,"version":"3.48.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012650"],"award-info":[{"award-number":["2022A1515012650"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515010887"],"award-info":[{"award-number":["2021A1515010887"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou","award":["2024A03J0919"],"award-info":[{"award-number":["2024A03J0919"]}]},{"name":"Science and Technology Program of Guangzhou","award":["202201020427"],"award-info":[{"award-number":["202201020427"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancer (BTC), as a relatively rare tumor, carries a poor prognosis. While immunotherapy combined with chemotherapy can extend survival, response rates remain low. Targeted therapies tailored to specific genetic mutations may improve outcomes when paired with immune checkpoint inhibitors. This report examines 2 cases of advanced BTC with distinct genetic alterations, treated with targeted therapy and immune checkpoint inhibitors, to assess efficacy and feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 45-year-old patient with a BRAF V600E-mutated intrahepatic cholangiocarcinoma received dabrafenib, trametinib, and durvalumab. This led to significant tumor reduction, enabling complete surgical resection with clear margins. Postoperative analysis showed a major pathological response. A 39-year-old patient with MET-amplified gallbladder cancer was treated with tepotinib, durvalumab, and chemotherapy, resulting in metastases regression and successful tumor downstaging. Surgery achieved no evidence of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combining targeted therapies with immune checkpoint inhibitors showed promising results in 2 patients with advanced BTC driven by specific genetic mutations. Significant tumor reduction and successful surgeries suggest this approach may improve resectability and outcomes. These cases highlight the potential of personalized treatment guided by genetic profiling. Further research is needed to confirm these findings and explore broader applications for this strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf374","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:46:36Z","timestamp":1765716396000},"source":"Crossref","is-referenced-by-count":0,"title":["Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports"],"prefix":"10.1093","volume":"30","author":[{"given":"Xin","family":"He","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changchang","family":"Jia","sequence":"additional","affiliation":[{"name":"Biotherapy Centre, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0336-091X","authenticated-orcid":false,"given":"Tiantian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2025121903322778400_oyaf374-B1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2025121903322778400_oyaf374-B2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2025121903322778400_oyaf374-B3","doi-asserted-by":"crossref","first-page":"100378","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"2025121903322778400_oyaf374-B4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025121903322778400_oyaf374-B5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2025121903322778400_oyaf374-B6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"2025121903322778400_oyaf374-B7","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"key":"2025121903322778400_oyaf374-B8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2025121903322778400_oyaf374-B9","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1535-7163.MCT-14-0290","article-title":"Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma","volume":"13","author":"Ilieva","year":"2014","journal-title":"Mol \u00adCancer Ther"},{"key":"2025121903322778400_oyaf374-B10","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/cancers14225489","article-title":"Triple combination of immune checkpoint inhibitors and BRAF\/MEK inhibitors in BRAFV600 melanoma: current status and future perspectives","volume":"14","author":"Welti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025121903322778400_oyaf374-B11","doi-asserted-by":"crossref","first-page":"114440","DOI":"10.1016\/j.yexcr.2025.114440","article-title":"BRAF V600E in cancer: exploring structural complexities, mutation profiles, and pathway dysregulation","volume":"446","author":"Bharti","year":"2025","journal-title":"Exp Cell Res"},{"key":"2025121903322778400_oyaf374-B12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025121903322778400_oyaf374-B13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/onci.20226","article-title":"Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma","volume":"1","author":"Hooijkaas","year":"2012","journal-title":"Oncoimmunology"},{"key":"2025121903322778400_oyaf374-B14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025121903322778400_oyaf374-B15","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/S0140-6736(20)31285-X","article-title":"Triple therapy for BRAFV600-mutated melanoma","volume":"395","author":"Ribas","year":"2020","journal-title":"Lancet"},{"key":"2025121903322778400_oyaf374-B16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"2025121903322778400_oyaf374-B17","doi-asserted-by":"crossref","first-page":"1073274820983013","DOI":"10.1177\/1073274820983013","article-title":"Targeting BRAF-Mutant biliary tract cancer: recent advances and future challenges","volume":"27","author":"Rizzo","year":"2020","journal-title":"Cancer Control"},{"key":"2025121903322778400_oyaf374-B18","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"key":"2025121903322778400_oyaf374-B19","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"2025121903322778400_oyaf374-B20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/oncolo\/oyae265","article-title":"Exceptional sustained long-term complete response to tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing durvalumab plus cisplatin and gemcitabine","volume":"29","author":"Reichinger","year":"2024","journal-title":"Oncologist"},{"year":"2025","author":"Cancer Research","key":"2025121903322778400_oyaf374-B21"},{"key":"2025121903322778400_oyaf374-B22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov"},{"key":"2025121903322778400_oyaf374-B23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell Commun Signal"},{"key":"2025121903322778400_oyaf374-B24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf374\/65884363\/oyaf374.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf374\/65884363\/oyaf374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf374\/65884363\/oyaf374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:32:44Z","timestamp":1766133164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf374\/8380176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf374","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"article-number":"oyaf374"}}